BACKGROUND
Subsets of myeloid-derived regulatory cells (MDRC), phenotypically similar to myeloid-derived suppressor cells found in cancer, have recently been appreciated as critical regulators of airway inflammation in mouse models of asthma.
OBJECTIVE
We test the hypothesis that subsets of airway MDRC contribute differentially to the inflammatory milieu in human asthma and chronic obstructive pulmonary disease (COPD).
METHODS
We used BAL to identify and characterize human airway MDRC from 10 normal, 9 mild asthmatic and 8 COPD subjects, none treated with inhaled or systemic corticosteroids. We defined subsets of airway MDRC by flow cytometry, the molecular mediators they produce and their abilities to regulate proliferation of polyclonally activated autologous T-lymphocytes.
RESULTS
We found substantial differences in the functional potential of MDRC subsets in normal, asthmatic and COPD subjects, with these differences regulated by the nitrosative and oxidative free radicals and cytokines they produced. Nitric oxide-producing MDRC suppressed and superoxide-producing MDRC enhanced proliferation of polyclonally activated autologous CD4 T-cells. HLA-DR+CD11+CD11c+CD163− superoxide-producing MDRC, which stimulated proliferation of autologous T-cells, comprised a high fraction of MDRC in airways of subjects with mild asthma or COPD, but not normals. CD11b+CD14+CD16−HLA-DR− nitric oxide-producing MDRC, which suppressed T-cell proliferation, were present in high numbers in airways of subjects with mild asthma, but not subjects with COPD or normals.
CONCLUSION
Subsets of airway MDRC conclusively discriminate mild asthmatics, subjects with COPD and normal subjects from each other. The distinctive activities of these MDRC in asthma and COPD may provide novel targets for new therapeutics in these common disorders.